Indications
Bevixa is a vascular endothelial growth factor-specific angiogenesis inhibitor. It is indicated for the treatment of metastatic colorectal cancer, given with intravenous 5-fluorouracil-based chemotherapy as first- or second-line treatment. It is also indicated for metastatic colorectal cancer, given with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy as second-line treatment in patients whose disease has progressed on a first-line regimen containing Bevixa. It is indicated for non-squamous non-small cell lung cancer, given with carboplatin and paclitaxel as first-line treatment of unresectable, locally advanced, recurrent or metastatic disease. It is indicated for glioblastoma, used as a single agent in adult patients with progressive disease following prior therapy; the effectiveness of Bevixa here is based on improvement in objective response rate, and no data are available demonstrating improvement in disease-related symptoms or survival with Bevixa. It is indicated for metastatic renal cell carcinoma in combination with interferon alfa. It is indicated for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, in persistent, recurrent, or metastatic disease. It is indicated for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that is either (1) platinum-resistant, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, or (2) platinum-sensitive, in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Bevixa as a single agent. Limitation of use: Bevixa is not indicated for adjuvant treatment of colon cancer.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Bevacizumab is a recombinant, humanized monoclonal IgG1 antibody. It binds to human vascular endothelial growth factor (VEGF) and blocks its biological activity, as shown in both in-vitro and in-vivo assay systems. Its framework regions are human, while the complementarity-determining regions come from a murine antibody that binds VEGF. The molecule weighs roughly 149 kD.
Bevacizumab is made in Chinese Hamster Ovary cells, grown in a nutrient medium that contains the antibiotic gentamicin. Gentamicin cannot be detected in the final product. What reaches the patient is a clear to slightly opalescent, colourless to pale brown, sterile solution with a pH of 6.2, given by intravenous infusion.
Pregnancy & Breastfeeding
Pregnancy: Based on animal studies and its mechanism of action, bevacizumab may cause fetal harm.
Lactation: No data are available on whether bevacizumab passes into human milk, or on its effects on milk production or on a breastfed infant. Human IgG is known to be present in breast milk, but published data suggest that antibodies in breast milk do not enter the neonatal and infant circulation in significant amounts. Because of the risk of serious adverse reactions in breastfed infants, nursing mothers are advised not to breastfeed while being treated with Bevacizumab.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.
Side Effects & Interactions
Side Effects
No side-effect data recorded yet.